Latest news with #EAU
Euronews
09-04-2025
- Health
- Euronews
Testicular cancer: What are the signs to look out for and how do you check you have it?
ADVERTISEMENT Testicular cancer may be rare, but it's the most common form of cancer facing young men. It's also one of the most treatable cancers if it's caught early. Survival rates are high, with 95 per cent of men under age 45 surviving at least five years after diagnosis, European data shows. But because there are few symptoms, men may not realise they have testicular cancer, leading to delays in diagnosis that can make treatment more complicated. Part of the problem is that 'there is no self-examination culture' due to social 'taboos,' said Dr Hendrik Van Poppel, a urologist on the board of the European Association of Urology (EAU) and co-chair of the inequalities network hosted by the European Cancer Organisation. Related 'Who knew a pair of undies could hold so much power': New underwear labels to raise cancer awareness With Testicular Cancer Awareness Month in full swing, here's what you need to know to take charge of your health. Who is at risk of testicular cancer? Testicular cancer affects about one in every 250 men in Europe, and it's the most common cancer among those under age 45 . Diagnoses peak in the late 20s and early 30s. Some men are at higher risk of testicular cancer, including those with a family history of it, men with HIV or fertility problems, white men, and those with cryptorchidism. Cryptorchidism is a condition where the testicles do not descend into the scrotum, which they normally do around the time a baby boy is born. About 5 to 10 per cent of men with testicular cancer had the condition, which can be fixed with surgery, as a child. What are the signs of testicular cancer? Van Poppel told Euronews Health that young men and teenage boys should do self-examinations while in a warm shower or bath, when the scrotum is relaxed. Check each testicle separately for lumps or changes. Related World Cancer Day: Forever chemicals in tap water might cause cancer to spread, study finds According to the EAU , most changes you might find during a self-exam are not cancer. But if you find a small, painless lump in the testicle it could be serious, so follow up with a doctor. Other warning signs include a testicle getting bigger or painful, or the scrotum feeling firm, hard, heavy, or achy, the UK National Health Service (NHS) said. Pain in your back or lower stomach, losing weight, having a cough or a hard time breathing or swallowing, and a sore chest can all be symptoms as well. What is life like after a testicular cancer diagnosis? Treatment typically involves surgery to remove the testicle, sometimes followed by chemotherapy or radiation. Some people opt to get an artificial testicle put in to replace the one they lost in surgery, according to the NHS. Related Men with higher quality sperm may have longer lifespan, new study finds Some testicular cancer treatments can affect fertility, meaning it could be harder to have children. Before beginning treatment, you may want to consider storing and banking your sperm, which could be used for fertility treatments in the future. If the cancer has spread to other parts of the body, it can be harder to treat. In that case, doctors may offer more intensive treatments or palliative care to manage your symptoms as long as possible. ADVERTISEMENT The bottom line, Van Poppel said, is that testicular cancer doesn't have to be a death sentence. 'Many of these guys who are discovered late, even metastatic, can be cured,' Van Poppel said. 'But the main goal should be timely detection'.
Yahoo
02-04-2025
- Business
- Yahoo
Former Just Salad CFO ‘deprived' of $1.2M bonus for ‘doing job too well,' says lawsuit
This story was originally published on To receive daily news and insights, subscribe to our free daily newsletter. The former CFO of restaurant chain Just Salad claims he was denied a $1.2 million payout not because he underperformed but because the company grew too much, too fast. Stefan Boyd is suing his former employer over the payment that he says is being kept from him due to a technicality. In a complaint filed in New York Supreme Court, the former CFO says that after he left the company in 2023, he was under the impression that if the company raised capital at a deemed valuation of $250 million or more by the end of 2024, he would be compensated. Around September 2024 the lawsuit says, Boyd learned that Just Salad had completed its planned capital raise, securing $200 million at a valuation close to $1 billion. In February of 2025, the company announced the funding round. The filings allege that Just Salad founder and CEO Nick Kenner told Boyd directly when he asked about his compensation that he was 'screwed' because the company's valuation exceeded expectations and the Equity Appreciation Unit plan — on which Boyd's separation payout was premised — had been terminated just two months prior. As a result, Kenner allegedly told Boyd he would receive nothing despite acknowledging that Boyd's work helped enable the company's nearly $1 billion valuation. However, the agreement, which was part of a separation agreement when Boyd left the company in 2023, tied a payout to a distribution event, which, in the EAU's plan, consists of the following: (a) a Sale of the Company or (b) an IPO; provided that the event also qualifies as a 'Change in Ownership or Effective Control' under IRS Code Section 409A. The term sale there is also defined as 'a sale of at least 30% of the membership interests or assets of the company unless the Board chooses to declare a smaller transaction as qualifying.' The technicality that Kenner references is that the amount of equity that Just Salad sold (20%) is less than what is defined as a sale (30%) in section A of the EAU. Due to this, Kenner and company argue Boyd isn't owed anything, although the lawsuit also claims other employees who were in similar positions were paid and are still actively receiving payments 'in the spirit' of the plan. 'Just Salad has adopted an absurd position,' the suit says. 'Boyd should be deprived of the intended reward for his work totaling around $1.2 million — because the value he created was too great; he did his job too well; the foundation he built was too strong; the Company grew too much and raised too much money (all while parting with too little of its equity).' A Just Salad representative said when Boyd left the company in 2023, he had 'a clear separation agreement that he helped craft and negotiate,' and since the terms of the agreement were not met, it did not 'stipulate' a payment.' Just Salad added, 'The accusations and purported statements made are categorically false, and we look forward to vigorously defending these allegations.' Boyd is suing to recover his unpaid wages, along with more than $5 million in additional damages. Recommended Reading CFO crimes, litigation, financial control failures, ethics violations and more Sign in to access your portfolio
Yahoo
25-03-2025
- Health
- Yahoo
Urine test could help spot recurring kidney cancer, researchers say
A simple urine test could accurately detect recurring kidney cancer in patients recovering from surgery for the disease, potentially sparing them from frequent follow-up scans, researchers suggest. The AUR87A study, led by Swedish researchers, included 134 patients who were treated at 23 hospitals in the UK, Europe, US and Canada. All had been diagnosed with clear cell renal cell carcinoma (ccRCC) – the most common type of kidney cancer – which had not spread beyond the kidney and was treated with surgery. Most patients had their kidney completely removed. This type of cancer returns in about a fifth of people, usually within one to two years. Patients are monitored with CT scans, with their frequency based on the level of individual risk. For the study, the group continued to have CT scans as part of their standard monitoring after the operation, alongside a urine test every three months. These tests analysed the profiles of certain sugar molecules in the urine, known as glycosaminoglycans, and gave patients a score out of 100, known as the GAGome score. After 18 months, cancer had returned in 15% of the group. The study found the urine test correctly detected recurrence in 90% of these patients. It also correctly ruled out recurring cancer in a little over half the patients who remained cancer-free. Saeed Dabestani, associate professor at Lund University and consultant urologist at Kristianstad Central Hospital in Sweden, said: 'CT scans often pick up small lesions that aren't large enough to biopsy, and we currently don't know whether they are a sign of the cancer returning or not. 'Our only option is to do more frequent scans to monitor more closely, which is unpleasant for patients and often brings little benefit. 'If you have a urine test that can accurately show whether the cancer has actually returned then you can better assess risk levels and reduce the frequency of the scans required. 'Based on the results we have so far, it's likely that we could safely halve the number of scans that patients have to undergo.' The findings are being presented at the at the European Association of Urology (EAU) Congress in Madrid and have been accepted for publication in the journal European Urology Oncology. Researchers are currently recruiting a second group of patients for the AUR87A study, which results expected towards the end of the year.
The Independent
24-03-2025
- Health
- The Independent
Urine test ‘could help spot recurring kidney cancer', researchers suggest
A simple urine test could accurately detect recurring kidney cancer in patients recovering from surgery for the disease, potentially sparing them from frequent follow-up scans, researchers suggest. The AUR87A study, led by Swedish researchers, included 134 patients who were treated at 23 hospitals in the UK, Europe, US and Canada. All had been diagnosed with clear cell renal cell carcinoma (ccRCC) – the most common type of kidney cancer – which had not spread beyond the kidney and was treated with surgery. Most patients had their kidney completely removed. This type of cancer returns in about a fifth of people, usually within one to two years. Patients are monitored with CT scans, with their frequency based on the level of individual risk. For the study, the group continued to have CT scans as part of their standard monitoring after the operation, alongside a urine test every three months. These tests analysed the profiles of certain sugar molecules in the urine, known as glycosaminoglycans, and gave patients a score out of 100, known as the GAGome score. After 18 months, cancer had returned in 15% of the group. The study found the urine test correctly detected recurrence in 90% of these patients. It also correctly ruled out recurring cancer in a little over half the patients who remained cancer-free. Saeed Dabestani, associate professor at Lund University and consultant urologist at Kristianstad Central Hospital in Sweden, said: 'CT scans often pick up small lesions that aren't large enough to biopsy, and we currently don't know whether they are a sign of the cancer returning or not. 'Our only option is to do more frequent scans to monitor more closely, which is unpleasant for patients and often brings little benefit. 'If you have a urine test that can accurately show whether the cancer has actually returned then you can better assess risk levels and reduce the frequency of the scans required. 'Based on the results we have so far, it's likely that we could safely halve the number of scans that patients have to undergo.' The findings are being presented at the at the European Association of Urology (EAU) Congress in Madrid and have been accepted for publication in the journal European Urology Oncology. Researchers are currently recruiting a second group of patients for the AUR87A study, which results expected towards the end of the year.
Yahoo
24-03-2025
- Health
- Yahoo
Urine test ‘could help spot recurring kidney cancer', researchers suggest
A simple urine test could accurately detect recurring kidney cancer in patients recovering from surgery for the disease, potentially sparing them from frequent follow-up scans, researchers suggest. The AUR87A study, led by Swedish researchers, included 134 patients who were treated at 23 hospitals in the UK, Europe, US and Canada. All had been diagnosed with clear cell renal cell carcinoma (ccRCC) – the most common type of kidney cancer – which had not spread beyond the kidney and was treated with surgery. Most patients had their kidney completely removed. This type of cancer returns in about a fifth of people, usually within one to two years. Patients are monitored with CT scans, with their frequency based on the level of individual risk. For the study, the group continued to have CT scans as part of their standard monitoring after the operation, alongside a urine test every three months. These tests analysed the profiles of certain sugar molecules in the urine, known as glycosaminoglycans, and gave patients a score out of 100, known as the GAGome score. After 18 months, cancer had returned in 15% of the group. The study found the urine test correctly detected recurrence in 90% of these patients. It also correctly ruled out recurring cancer in a little over half the patients who remained cancer-free. Saeed Dabestani, associate professor at Lund University and consultant urologist at Kristianstad Central Hospital in Sweden, said: 'CT scans often pick up small lesions that aren't large enough to biopsy, and we currently don't know whether they are a sign of the cancer returning or not. 'Our only option is to do more frequent scans to monitor more closely, which is unpleasant for patients and often brings little benefit. 'If you have a urine test that can accurately show whether the cancer has actually returned then you can better assess risk levels and reduce the frequency of the scans required. 'Based on the results we have so far, it's likely that we could safely halve the number of scans that patients have to undergo.' The findings are being presented at the at the European Association of Urology (EAU) Congress in Madrid and have been accepted for publication in the journal European Urology Oncology. Researchers are currently recruiting a second group of patients for the AUR87A study, which results expected towards the end of the year.
